Literature DB >> 29541353

Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.

Robert B Kargbo1.   

Abstract

Year:  2018        PMID： 29541353      PMCID： PMC5846031          DOI： 10.1021/acsmedchemlett.8b00068

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

1.  Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease.

Authors:  Andre Richters; Angela N Koehler
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

2.  Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells.

Authors:  Yoshitaka Sunami; Marito Araki; Shin Kan; Akihiro Ito; Yumi Hironaka; Misa Imai; Soji Morishita; Akimichi Ohsaka; Norio Komatsu
Journal:  J Biol Chem       Date:  2017-01-04       Impact factor: 5.157

Review 3.  Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis.

Authors:  Emanuely Silva Chrun; Filipe Modolo; Filipe Ivan Daniel
Journal:  Pathol Res Pract       Date:  2017-06-28       Impact factor: 3.250

4.  Expression of DHA-Metabolizing Enzyme Alox15 is Regulated by Selective Histone Acetylation in Neuroblastoma Cells.

Authors:  Christabel Fung-Yih Ho; Claire Poh-Ee Bon; Yee-Kong Ng; Deron R Herr; Jui-Sheng Wu; Teng-Nan Lin; Wei-Yi Ong
Journal:  Neurochem Res       Date:  2017-12-12       Impact factor: 3.996

5.  Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.

Authors:  Ian F Harrison; Andrew D Smith; David T Dexter
Journal:  Neurosci Lett       Date:  2017-12-19       Impact factor: 3.046
  5 in total
  1 in total

Review 1.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.